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Summary
Background: There is limited evidence about useful therapeutic interventions for
patients with acute hyperglycemia (AH) after acute myocardial infarction (AMI).
Methods: We studied 2433 consecutive non-diabetic AMI patients who underwent
percutaneous coronary intervention (PCI) within 24 h after the onset. Patients were
divided into two groups according to the presence or absence of AH (admission serum
glucose level ≥11.1mmol/l). We assessed the association between intracoronary
thrombectomy and the clinical outcome in AMI patients with AH.
Results: Patients with AH had more risk factors than those without AH. The 30-day
mortality rate of patients with AH was signiﬁcantly higher than that of those without
(11.7% vs 1.7%, p < 0.001). Among patients with AH, the 30-day mortality rate was
signiﬁcantly lower for those with intracoronary thrombectomy than those without it
(4.9% vs 17.2%, p = 0.004). Among patients without AH, however, the 30-day mortality
rate was similar between those with and without intracoronary thrombectomy (1.5%
vs 1.9%, p =NS). Multivariate analysis showed that intracoronary thrombectomy was
associated with an improved 30-day mortality rate for patients with AH (hazard
ratio: HR 0.184, 95% CI 0.057—0.598, p = 0.005).
∗ Corresponding author. Tel.: +81 6 6879 6612; fax: +81 6 6879 6613.
E-mail address: satoz@medone.med.osaka-u.ac.jp (H. Sato).
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Conclusions: In AMI patients with AH, intracoronary thrombectomy prior to PCI might
improve the 30-day mortality rate.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights© 2009 Japanese Colleg
reserved.
Introduction
On admission for acute myocardial infarction (AMI),
acute hyperglycemia (AH) is often observed in non-
diabetic patients as well as in diabetic patients
[1,2]. Several studies have found an association
between AH in non-diabetic patients and an adverse
clinical outcome after AMI [3—8], suggesting that
AH may represent either stress hyperglycemia due
to a large infarct or cardiogenic shock [5,6,9], or be
secondary to pre-existing or undiagnosed diabetes
[1,4]. It has been reported that AH might cause
microvascular damage [10] or increase coagulabil-
ity [11,12], resulting in the no-reﬂow phenomenon
that might induce more extensive myocardial dam-
age and impair left ventricular function [7,13].
Despite the adverse clinical impact of AH [5,6],
there are limited data about interventions that
may have a beneﬁcial effect in patients with
AH after AMI. On the other hand, it has been
reported that performing intracoronary thrombec-
tomy before percutaneous coronary intervention
(PCI) might improve coronary perfusion, salvage
more myocardium, and reduce mortality in patients
with AMI, especially in those with diabetes or
at high risk [14—19]. Therefore, we examined
the hypothesis that intracoronary thrombectomy
improves the clinical outcome after AMI in patients
with AH by reviewing the database of the Osaka
Acute Coronary Insufﬁciency Study (OACIS) registry.
Methods
Study population
Patients were identiﬁed in the OACIS registry. A
detailed description of the OACIS has been pub-
lished elsewhere [20—22]. Brieﬂy, the OACIS is
a prospective multicenter observational study, in
which 25 participating hospitals from the Osaka
region of Japan record demographic, procedu-
ral, and outcome data, and collect blood samples
from patients with AMI. The study protocol was
approved by each hospital’s ethical committee and
written informed consent was provided by each
patient at the time of registration. The registry is
designed to collect uniform prospective data on AMI
patients that can be used to assess clinical vari-ables, therapeutic procedures, and clinical events.
The diagnosis of AMI required 2 of the following
3 criteria: (1) a history of central chest pressure,
pain, or tightness lasting for 30min or more; (2) ST-
segment elevation greater than 0.1mV in at least 1
limb lead or 2 precordial leads; and (3) an increase
in the serum creatine kinase (CK) concentration
to more than twice the upper limit of normal. All
patients presenting within 1 week after the onset
of AMI were registered prospectively as soon as a
diagnosis of AMI was made.
Among 8025 consecutive AMI patients registered
in the OACIS between April 1998 and December
2007, 4597 patients who fulﬁlled the follow-
ing criteria were enrolled in the present study:
(1) coronary angiography and coronary interven-
tion performed within 24 h after the onset of
AMI; and (2) the plasma glucose level and gly-
cated hemoglobin (HbA1c) level were measured
on admission. To minimize the inﬂuence of pre-
existing diabetes mellitus (DM) on hyperglycemia,
we excluded patients who had been diagnosed
as having DM or were on treatment for DM
(diet, tablets, or insulin) and patients with an
admission HbA1c >5.8%. A total of 2433 patients
fulﬁlled the criteria. These patients were divided
into 2 groups according to whether they had a
plasma glucose≥ 11.1mmol/l on admission (AH
group: N = 231) or not (non-AH group: N = 2202). We
also divided the AH and non-AH groups into sub-
groups according to whether or not intracoronary
thrombectomy was done before PCI. Hypertension
was deﬁned as a history of systolic blood pressure
≥140mmHg, diastolic blood pressure ≥90mmHg,
or antihypertensive therapy. Hyperlipidemia was
deﬁned as fasting total cholesterol ≥220mg/dl,
fasting triglycerides ≥150mg/dl, or antilipidemic
therapy. Smoking was deﬁned as currently or pre-
viously smoking. Before hospital discharge (mean
14 days after the onset), 2011 patients underwent
echocardiography at each hospital. The following
variables were measured: end-diastolic dimension
(Dd) and end-systolic dimension (Ds).
Coronary angiography and PCIInformed consent for cardiac catheterization and
PCI was obtained from all patients at each hospital.
Coronary angiography was performed immediately
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Table 1 Clinical, angiographic characteristics and major medications during hospitalization of the study population according to absence/presence of acute
hyperglycemia with and without intracoronary thrombectomy.
Variables Non-AH group, ICT AH group, ICT AH vs non-AH
No (N = 1218) Yes (N = 984) p-Value No (N = 128) Yes (N = 103) p-value p-Value
Clinical characteristics
Men 76.4% 78.8% 0.200 72.7% 68.9% 0.562 0.033
Age (yrs) 65.6± 11.8 64.0± 12.4 0.099 68.7± 11.9 68.0± 11.8 0.671 <0.001
Body mass index (kg/m2) 23.4± 3.4 23.7± 3.3 0.364 22.5± 3.1 22.7± 3.4 0.306 <0.001
Hypertension 55.3% 52.3% 0.183 52.3% 50.5% 0.793 0.489
Hyperlipidemia 42.6% 40.7% 0.362 31.3% 30.1% 0.887 0.001
Smoker 62.8% 67.0% 0.044 54.7% 53.4% 0.895 0.002
History of myocardial infarction 10.9% 11.0% 1.000 10.2% 5.8% 0.336 0.220
History of angina 22.0% 21.7% 0.917 24.2% 20.4% 0.529 0.803
ST elevation myocardial infarction 85.8% 90.3% 0.001 87.5% 94.2% 0.114 0.285
Killip classiﬁcation > I 12.9% 11.4% 0.295 40.6% 34.0% 0.340 <0.001
Killip classiﬁcation = IV 2.5% 2.3% 0.274 20.3% 21.4% 0.404 <0.001
Time from symptom onset to admission (h) 2.50(1.17—6.50) 2.33(1.00—5.65) 0.032 1.92(1.00—4.18) 1.70(0.93—2.67) 0.147 <0.001
Glycated hemoglobin A1c (%) 5.15± 0.3 5.22± 0.3 0.729 5.14± 0.4 5.25± 0.4 0.837 0.742
Admission glucose levels (mmol/l) 7.27± 1.4 7.37± 1.5 0.119 14.40± 3.5 14.48± 3.6 0.872 <0.001
Angiographic characteristics
Multivessel coronary disease 35.3% 32.9% 0.259 46.1% 36.9% 0.181 0.020
Collateral circulation 37.4% 39.9% 0.235 35.2% 37.9% 0.682 0.523
Infarction related artery
Right coronary artery 32.7% 38.9% <0.001 35.1% 41.7% 0.588 0.389
Left anterior descending artery 48.4% 43.8% 0.004 44.5% 46.6% 0.791 0.628
Circumﬂex artery 14.6% 13.6% 0.539 10.2% 3.9% 0.080 0.003
Diagonal or bypass graft 3.5% 2.8% 0.433 0.8% 1.0% 1.000 0.021
Left main coronary artery 0.8% 0.9% 0.821 9.4% 6.8% 0.631 <0.001
Initial TIMI ﬂow grade 3 18.1% 8.1% <0.001 16.4% 8.7% 0.115 0.840
Stent implantation 61.5% 83.3% <0.001 69.5% 89.3% <0.001 0.025
Medications during hospitalization
Aspirin 99.7% 99.4% 0.357 99.2% 99.0% 1.000 0.318
ACE inhibitors or AT1 antagonists 81.4% 87.0% <0.001 61.7% 74.8% 0.047 <0.001
Beta-blockers 42.9% 50.1% 0.001 42.2% 50.5% 0.233 1.000
Statin 37.7% 41.0% 0.124 25.0% 33.0% 0.190 0.002
Insulin or any oral antidiabetics 1.8% 1.2% 0.283 2.3% 0% 0.498 1.000
AH, acute hyperglycemia; ICT, intracoronary thrombectomy; ACE, angiotensin-converting enzyme; AT, angiotensin.
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after admission. Coronary artery stenosis was con-
sidered to be clinically signiﬁcant if the luminal
diameter was reduced by ≥75%. The presence
of collaterals supplying the infarct-related artery
was assessed by observing whether opaciﬁcation
occurred from a site distal to the culprit lesion
on coronary angiography. Patients underwent PCI
according to current guidelines with a conven-
tional catheter-based system. Perfusion of the
infarct-related artery was assessed according to the
Thrombolysis in Myocardial Infarction (TIMI) study
classiﬁcation [23], and the ﬁnal TIMI ﬂow grade was
determined from the ﬁnal angiograms. Among the
patients receiving intracoronary thrombectomy, a
RESCUE catheter (Boston Scientiﬁc Scimed, Inc.,
Maple Grove, MN, USA), a Thrombuster catheter
(Kaneka Medix Corp., Osaka, Japan), a TVAC
catheter (Nipro, Osaka, Japan), and an Export aspi-
ration catheter (PercuSurge System, Medtronic AVE,
Danvers, MA, USA) were used in 33.9%, 54.9%, 3.9%,
and 7.3% of the patients, respectively.
Statistical analysis
The clinical end-point for this study was all-cause
mortality after AMI. Results are expressed as the
mean± SD or median with 25th and 75th per-
centiles for continuous variables, while qualitative
data are presented as numbers or percentages. Dif-
ferences of continuous variables between groups
were compared by Student’s t-test, while cate-
gorical variables were compared by the chi-square
test. Survival curves were constructed by the
Kaplan—Meier method and the signiﬁcance of dif-
ferences in survival were assessed by the log-rank
test. A multiple logistic regression model was used
to assess whether intracoronary thrombectomy
was independently associated with an improved
30-day mortality. The variables included in this
model were age, male sex, body mass index (BMI),
t
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u
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Table 2 Mortality and causes of death at day 30 according
without intracoronary thrombectomy.
Non-AH group, ICT
No (N = 1218) Yes (N = 984)
All cause death 1.9% 1.5%
Cardiac death 1.7% 1.4%
Heart failure 1.2% 0.8%
Re-infarction 0% 0%
Mechanical complication 0.2% 0.4%
Arrhythmia 0.2% 0.2%
Other cardiac death 0.1% 0%
Non-cardiac death 0.2% 0.1%M. Usami et al.
ypertension, hyperlipidemia, smoking, history of
yocardial infarction, history of angina, ST eleva-
ion myocardial infarction, Killip class >I, the time
rom symptom onset to admission, angiographic
ndings (multivessel disease, collateral circulation,
nd initial TIMI grade ﬂow), and performance of
tenting. Analysis of data was performed by using
PSS statistical software (version 11.0, SPSS Japan
nc., Tokyo, Japan). For all analyses, statistical sig-
iﬁcance was deﬁned as p < 0.05.
esults
ntracoronary thrombectomy was performed in 103
atients (44.6%) among the 231 patients with AH,
nd in 984 patients (44.7%) among the 2202 patients
ithout AH. The clinical and angiographic char-
cteristics, as well as major medications during
ospitalization, are listed in Table 1 for the four
ubgroups. Patients with AH were older and more
ften female than those without AH. The preva-
ence of classic risk factors such as hyperlipidemia
r smoking was lower in patients with AH, but
hey had a higher Killip class on admission and a
horter interval to admission from symptom onset
han patients without AH. HbA1c on admission did
ot differ between the patients with and without
H. The patients with AH more frequently had mul-
ivessel coronary disease and a culprit lesion in
he left main coronary artery. Although clinical and
ngiographic characteristics differed between the
atients with and without AH, these did not differ
etween the patients with and without intracoro-
ary thrombectomy in patients with AH. Regardless
f AH, among the patients treated by intracoronary
hrombectomy, the percentage of patients who had
culprit lesion in the right coronary artery or
nderwent coronary stenting was higher, and the
ercentage of patients with an initial TIMI ﬂow of
to absence/presence of acute hyperglycemia with and
AH group, ICT
p-Value No (N = 128) Yes (N = 103) p-Value
0.622 17.2% 4.9% 0.004
0.611 16.4% 4.9% 0.006
0.521 11.7% 4.9% 0.098
1.6% 0% 0.504
0.707 2.3% 0% 0.256
1.000 0.8% 0% 1.000
1.000 0% 0%
1.000 0.8% 0% 1.000
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Figure 1 Kaplan—Meier estimates of survival after
AMI according to study groups (log-rank test for all
comparisons, p < 0.001). Group 1 indicates patients with-
out acute hyperglycemia treated without intracoronary
thrombectomy; Group 2, patients without acute hyper-
glycemia treated with intracoronary thrombectomy;
Group 3, patients with acute hyperglycemia treated
without intracoronary thrombectomy; Group 4, patients
with acute hyperglycemia treated with intracoronary
thrombectomy. The 30-day mortality rate in patients
with acute hyperglycemia treated with intracoronary
thrombectomy (Group 4) was improved toward similar
level of patients without acute hyperglycemia.hrombectomy might improve 30-day mortality in A
rade 3 was lower than those without intracoro-
ary thrombectomy. The percentage of patients
eing treated with angiotensin-converting enzyme
nhibitors, angiotensin receptor antagonists, and
tatins was higher among those without AH. Few
atients started insulin or oral antidiabetic agents
uring hospitalization.
There were 65 deaths at day 30 in the present
tudy. Mortality and causes of death are shown in
able 2. The 30-day mortality rate of patients with
H was signiﬁcantly higher than that of those with-
ut it (11.7% vs 1.7%, p < 0.001). Among the patients
ithout AH, the 30-day mortality rate was simi-
ar between those with and without intracoronary
hrombectomy (1.5% vs 1.9%, p =NS). Among the
atients with AH, however, the 30-day mortality
ate of those with intracoronary thrombectomy was
igniﬁcantly lower than that of those without intra-
oronary thrombectomy (4.9% vs 17.2%, p = 0.004).
he difference in the Kaplan—Meier estimate was
igniﬁcant by the log-rank test (p = 0.001) (Fig. 1).
nivariate analysis revealed a beneﬁcial effect of
ntracoronary thrombectomy on the 30-day mortal-
ty of patients with AH [hazard ratio (HR) 0.266, 95%
I 0.101—0.701, p = 0.007], whereas intracoronary
hrombectomy did not show a beneﬁcial effect for
atients without AH (HR 0.804, 95% CI 0.419—1.541,
= 0.511). Because there were differences in base-ine clinical and angiographic characteristics among
he 4 subgroups, we also assessed the beneﬁcial
ffect of intracoronary thrombectomy on 30-day
ortality by multivariate analysis. After adjust-
ent for clinical and angiographic characteristics,
Table 3 Univariate and multivariate analysis for 30-day mortality after AMI.
30-Day death Non-AH group AH group
Hazard ratio 95% CI p-Value Hazard ratio 95% CI p-Value
Univariate
Age 1.071 1.038—1.104 <0.001 1.058 1.020—1.097 0.002
Male 0.812 0.394—1.672 0.572 0.665 0.304—1.452 0.306
BMI 0.990 0.892—1.098 0.846 0.920 0.806—1.051 0.219
Killip class > I 4.757 2.482—9.117 <0.001 3.501 1.573—7.793 0.002
Multivessel disease 1.732 0.916—3.275 0.091 4.270 1.805—10.10 0.001
Intracoronary thrombectomy 0.804 0.419—1.541 0.511 0.266 0.101—0.701 0.007
Multivariate
Age 1.033 0.989—1.079 0.147 1.055 0.994—1.119 0.076
Male 1.121 0.401—3.129 0.828 0.819 0.215—3.110 0.769
BMI 0.969 0.848—1.108 0.645 1.027 0.851—1.240 0.780
Killip class > I 4.994 2.084—11.70 <0.001 1.758 0.541—5.706 0.348
Multivessel disease 1.210 0.492—2.977 0.679 4.365 1.170—16.28 0.028
Intracoronary thrombectomy 1.185 0.486—2.887 0.709 0.184 0.057—0.598 0.005
AH, acute hyperglycemia; CI, conﬁdence interval. The variables included in the model were age, male gender, body mass index
(BMI), hypertension, hyperlipidemia, smoking, a history of myocardial infarction, a history of angina, ST-elevation myocardial
infarction, Killip class > I, time from symptom onset to admission, angiographic ﬁndings (including multivessel disease, collateral
circulation, and initial TIMI grade ﬂow), use of intracoronary thrombectomy, and use of stenting.
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Table 4 The incidence of ﬁnal TIMI ﬂow grade 3, the peak CK, and echocardiographic variables according to
absence/presence of acute hyperglycemia with and without intracoronary thrombectomy.
Non-AH group, ICT AH group, ICT
No (N = 1218) Yes (N = 984) p-Value No (N = 128) Yes (N = 103) p-Value
Final TIMI ﬂow grade 3 88.7% 90.3% 0.210 82.8% 90.3% 0.126
Peak CK (IU/l) 2663± 2590 2959± 2341 0.006 5252± 4974 4655± 3342 0.300
Echocardiography (N = 958) (N = 876) (N = 88) (N = 89)
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End-systolic dimension (mm) 34.9± 10.4 35.7
CK, creatine kinase.
its beneﬁcial effect remained signiﬁcant among
patients with AH (HR 0.184, 95% CI 0.057—0.598,
p = 0.005) (Table 3). On the other hand, a beneﬁcial
effect of intracoronary thrombectomy on 30-day
mortality was not seen in patients without AH.
There was a non-signiﬁcant increase in the inci-
dence of ﬁnal TIMI ﬂow grade 3 (90.3% vs 82.8%,
p = 0.126) and non-signiﬁcant decrease in peak
CK (4655± 3342 IU/l vs 5252± 4974 IU/l, p = 0.300)
between AH patients with and without intracoro-
nary thrombectomy. Furthermore, the end-diastolic
dimension assessed by echocardiography at chronic
phase after AMI was signiﬁcantly smaller in patients
undergoing intracoronary thrombectomy than in
those without it (49.4± 5.4mm vs 52.4± 6.8mm,
p = 0.001) (Table 4).
Discussion
Considerable attention has been focused on the
acute treatment of patients with AMI and AH
[24—26]. To our knowledge, this is the ﬁrst study to
demonstrate an association between intracoronary
thrombectomy before PCI and improved 30-day
mortality of non-diabetic patients with AH after
AMI.
Although it is difﬁcult to determine the mech-
anisms leading to the efﬁcacy of intracoronary
thrombectomy, there are several possible explana-
tions. In this study, mortality due to cardiac causes
and/or heart failure was lower in AH patients with
intracoronary thrombectomy than in those without
(Table 2). So, it may be suggested intracoronary
thrombectomy might prevent or improve heart fail-
ure due to left ventricular remodeling after AMI and
reduce cardiac death. Left ventricular remodeling
has been recognized as a major predictor of heart
failure and cardiovascular death after AMI [27—29],
and a recent study by Bauters et al., showed
that stress hyperglycemia was an independent pre-
dictor of left ventricular remodeling after the
ﬁrst anterior myocardial infarction in non-diabetic
s
T
o
r9 0.782 52.4± 6.8 49.4± 5.4 0.001
.7 0.201 37.2± 9.1 35.3± 7.2 0.128
atients [30]. Previous studies have suggested that
H could be associated with more extensive infarc-
ion [6,31]. In this study, there was non-signiﬁcant
ecrease in peak CK between AH patients with
nd without intracoronary thrombectomy. Further-
ore, the end-diastolic dimension assessed by
chocardiography at chronic phase after AMI was
igniﬁcantly smaller in patients undergoing intra-
oronary thrombectomy than in those without it
Table 4), suggesting that intracoronary thrombec-
omy might reduce left ventricular remodeling in
H patients. It will be necessary to conﬁrm whether
ntracoronary thrombectomy reduces left ventricu-
ar remodeling by further investigation.
Intracoronary thrombectomy might also prevent
r improve the no-reﬂow phenomenon. Iwakura et
l. reported that AH was associated with no-reﬂow
n contrast echocardiography [13]. Ishihara et
l. reported that angiographic no-reﬂow occurred
ore frequently in patients with AH and they sug-
ested that impaired microvascular function might
ontribute to this outcome [7]. The no-reﬂow phe-
omenon is a predictor of infarct size and an
dverse outcome after AMI [32,33]. Although the
revalence of the no-reﬂow phenomenon was not
ssessed in this study, there was a tendency to
ncrease the incidence of ﬁnal TIMI ﬂow grade 3
n AH patients with intracoronary thrombectomy
Table 4). It has been also reported that intracoro-
ary thrombectomy reduces the occurrence of the
o-reﬂow phenomenon [34], so it is possible that
ntracoronary thrombectomy reduced the no-reﬂow
henomenon and hence improved the prognosis of
atients with AH.
In this study, some AH patients may have been
ndiagnosed diabetics who ﬁtted the criteria for
M. Buell et al investigated the diagnosis of dia-
etes in 4935 patients and found that an HbA1c
f 5.8% yielded the highest sensitivity (86%) and
peciﬁcity (92%) in their study population [35].
herefore, we used an HbA1c of 5.8% as the cut-
ff value to exclude diabetes. However, several
ecent studies have shown that abnormal glucose
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[
[hrombectomy might improve 30-day mortality in A
olerance diagnosed by the oral glucose tolerance
est (OGTT) might be common in AMI patients with
ndiagnosed diabetes [36—38]. Thus, an OGTT is
ecessary to completely exclude diabetes. In this
tudy, we did not obtain OGTT data, but we rou-
inely measured HbA1c at admission. As shown in
able 1, few patients were newly treated with
nsulin or oral antidiabetic agents, suggesting that
ur subjects might not include enough potential
iabetics to change the results. Because it has been
eported that an HbA1c of 5.2% completely excludes
iabetes [39], we also assessed the subjects who
ad HbA1c levels of 5.2% or lower. The number of
atients was too small for multivariate analysis, but
e obtained the same results as in the full study
opulation by univariate analysis (data not shown).
imitations
his study had several limitations. First, we did
ot assess the number of aspiration procedures
r the total thrombus burden that was removed.
econd, it was an observational study and was
ot randomized. This means that several baseline
linical and angiographic characteristics differed
mong our four subgroups, and there may have been
otential confounding factors even after adjust-
ent for these differences in baseline clinical and
ngiographic characteristics. However, our subjects
eﬂected the ‘real world’ population because they
ere typical unselected AMI patients who received
CI early after symptom onset and admission to a
igh-volume hospital in a large city.
onclusion
ur ﬁndings suggest that non-diabetic patients
ho show acute hyperglycemia after AMI have
markedly better outcome when intracoronary
hrombectomy is done with PCI.
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